EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gaucher Disease: A Glance from a Medicinal Chemistry Perspective

Filippo Prencipe, Chiara Barzan, Chiara Savian, Giampiero Spalluto, Emanuele Carosati iD, Marco De Amici, Giorgio Mosconi, Teresa Gianferrara, Stephanie Federico, Tatiana Da Ros iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202300641 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2024. Verfasst von Filippo Prencipe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy. Hauptthemen laut MEDLINE: Gaucher Disease, Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 138 Literaturangaben. Gefördert von: MUR-FSE REACT EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rare diseases are particular pathological conditions affecting a limited number of people and few drugs are known to be effective as therapeutic treatment. Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, belongs to this class of disorders, and it is considered the most common among the Lysosomal Storage Diseases. The two main therapeutic approaches are the Enzyme Replacement Therapy (ERT) and the Substrate Reduction Therapy (SRT). ERT, consisting in replacing the defective enzyme by administering a recombinant enzyme, is effective in alleviating the visceral symptoms, hallmarks of the most common subtype of the disease whereas it has no effects when symptoms involve CNS, since the recombinant protein is unable to significantly cross the Blood Brain Barrier. The SRT strategy involves inhibiting glucosylceramide synthase (GCS), the enzyme responsible for the production of the associated storage molecule. The rational design of new inhibitors of GCS has been hampered by the lack of either the crystal structure of the enzyme or an in‐silico model of the active site which could provide important information regarding the interactions of potential inhibitors with the target, but, despite this, interesting results have been obtained and are herein reviewed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseaseEnzyme InhibitorsHumansGlucosyltransferasesChemistry, PharmaceuticalGlucosylceramidaseEnzyme Replacement TherapyMolecular Structure

Stichwörter der Autor:innen

Gaucher DiseaseGlucosylceramide Synthase InhibitorsRare DiseaseSubstrate Reduction Therapy

Substanzen

Enzyme InhibitorsGlucosyltransferasesGlucosylceramidaseceramide glucosyltransferase

Autor:innen und Institutionen

  • Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy.
  • Molecular Genetics Institute, CNR Via Abbiategrasso 207, 27100, Pavia, Italy.
  • Department of Pharmaceutical Sciences, University of Milano Via Luigi Mangiagalli 25, 20133, Milano, Italy.
  • Fidia Farmaceutici Via Ponte della Fabbrica 3/A, 35021, Abano Terme, Italy.

ORCID-Profile: Emanuele Carosati, Tatiana Da Ros

Förderung

  • MUR-FSE REACT EU

Zitieren

APA

Prencipe, F., Barzan, C., Savian, C., Spalluto, G., Carosati, E., De Amici, M., Mosconi, G., Gianferrara, T., Federico, S., & Da Ros, T. (2024). Gaucher Disease: A Glance from a Medicinal Chemistry Perspective. ChemMedChem. https://doi.org/10.1002/cmdc.202300641

Vancouver

Prencipe F, Barzan C, Savian C, Spalluto G, Carosati E, De Amici M, et al. Gaucher Disease: A Glance from a Medicinal Chemistry Perspective. ChemMedChem. 2024. doi:10.1002/cmdc.202300641

BibTeX
@article{Prencipe2024,
  author = {Prencipe, Filippo and Barzan, Chiara and Savian, Chiara and Spalluto, Giampiero and Carosati, Emanuele and De Amici, Marco and Mosconi, Giorgio and Gianferrara, Teresa and Federico, Stephanie and Da Ros, Tatiana},
  title = {Gaucher Disease: A Glance from a Medicinal Chemistry Perspective},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202300641}
}
Kostenlos starten →